Today’s “Prostate Cancer and You” podcast features Dr. Adam Kibel is chair of the department of urology at Mass General Brigham. In this conversation with host Jordan Rich, Dr. Kibel discusses a clinical trial focused on using genetic data and MRI to improve early detection of prostate cancer. The trial, involving men aged 40-69, aims to identify high-risk individuals through genetic testing and targeted screening. Dr. Kibel discusses the importance of clinical trials as well as the promise of this particular study to improve detection, treatment, and even prevention of prostate cancer in the future.

You can learn more about the study at https://rally.massgeneralbrigham.org/study/prostate_polygenic_risk_score.

Dr. Adam S. Kibel is chair of urology at Mass General Brigham. In addition, he is the Elliott Carr Cutler Professor of Surgery at Harvard Medical Medicine and chairman of the Harvard Urology Residency Program. Dr. Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency at the Harvard Urology Program, and completed his fellowship at the Brady Urologic Institute at Johns Hopkins.

In this second of a two-part podcast episode, Dr. Todd Cohen discusses the role of PSMA PET imaging in prostate cancer active surveillance, highlighting its potential to replace invasive biopsies. Cohen emphasizes the importance of communication and family involvement in active surveillance protocols. Advanced imaging technologies are evolving, offering hope for less invasive and more effective cancer management.

Dr. Todd Cohen earned his MD from the University of Rochester and completed a Urology residency at the Cleveland Clinic, followed by a fellowship at Duke. He founded Piedmont Urology in Charlotte, NC, and co-founded Carolina Urology Partners, serving as CEO for nine years. He held leadership roles at Myriad Genetics and currently serves as VP of Medical Affairs at Blue Earth Diagnostics.

In this first of a two-part podcast episode of “Prostate Cancer and You,” brought to you in part by Blue Earth Diagnostics, Dr. Todd Cohen, Blue Earth Diagnostics vice-president of medical affairs, discusses the practice of active surveillance in prostate cancer screening. Cohen explains the advancements in imaging, particularly PSMA PET scans, which have revolutionized prostate cancer detection. He also differentiates between active surveillance and watchful waiting, emphasizing the importance of individualized care and patient commitment in active surveillance.

Dr. Todd Cohen earned his MD from the University of Rochester and completed a Urology residency at the Cleveland Clinic, followed by a fellowship at Duke. He founded Piedmont Urology in Charlotte, NC, and co-founded Carolina Urology Partners, serving as CEO for nine years. He held leadership roles at Myriad Genetics and currently serves as VP of Medical Affairs at Blue Earth Diagnostics.

Today’s “Prostate Cancer and You” podcast features Dr. Jean Joseph, chairman of the department of urology at the University of Rochester Medical Center and keynote at the May 2025 MPCC Symposium. In this conversation with host Jordan Rich, Dr. Joseph furthers his keynote topics, discussing the history, benefits, and future development of robotic surgery for prostate cancer. The technology, initially developed for cardiac surgery, is less invasive than traditional surgery and has significantly reduced complications and side effects, allowing for a quicker recovery. 

Jean V. Joseph, MD, is W.W. Scott Professor and chairman of the department of urology at the University of Rochester Medical Center. He specializes in robotic surgery for urologic diseases, particularly prostate cancer. His research interests include surgical innovation, applications of novel robotic technology, and patient outcomes. Dr. Joseph completed a master class in laparoscopic prostatectomy at the Institute Mutualiste Montsouris (Paris, France) and holds a master’s in business administration from the Rochester Institute of Technology. 

In this second of a two-part podcast episode detailing new treatments for prostate cancer, Dr. Phillip Davis and Dr. Dan Stevens highlight the increasing accessibility of molecular imaging and radioligy and therapy across the US and the potential for earlier use of these technologies. They also discuss the promise of future advancements including personalized cancer treatments, the use of new radioactive isotopes, and the integration of AI in imaging and workflows. Both doctors stress the rapid developments in prostate cancer detection and treatment, encouraging patients to stay informed and involved in their care.

In this first of a two-part podcast episode, Dr. Phillip Davis and Dr. Dan Stevens follow up on the symposium topic of “New Treatments for Prostate Cancer.” In Part I, Dr. Philip Davis explains molecular imaging, which uses a low dose of radioactive medicine to detect cancer and other diseases early, as well as providing doctors with both anatomic and functional information on the cancer cells. Dr. Dan Stevens details radioligy and therapy, which uses radioactive isotopes to target cancer cells more precisely than traditional radiation therapy. Both technologies offer improved treatment options, enhancing patient outcomes.

Today’s podcast in the “Prostate Cancer and You” series features Dr. Preston Sprenkle, Associate Professor of Urology at Yale University, and Robert Palmer, a marketing executive and prostate cancer survivor. In this conversation with host Jordan Rich, Bob Palmer discusses his experience of incision-free ablation intervention as a cancer treatment. Here is a link to more details about Bob’s choice of ablation therapy using the TULSA Procedure: https://www.houstoniamag.com/sponsored/2024/04/pro-gives-men-with-prostate-disease-a-new-lease-on-life

Thanks to Bob Palmer for sharing his story on this podcast, sponsored in part by Profound Medical. Learn more about Profound Medical and TULSA-PRO at https://profoundmedical.com/new-tulsa/.

Today’s podcast in the “Prostate Cancer and You” series features Dr. Fay Shtern, the president of AdMeTech Foundation. In this conversation, Dr. Shtern and host Jordan Rich discuss the AdMeTech Foundation’s Prostate Cancer Equity Program and how men in and out of Massachusetts can participate.

For more information on AdMeTech Foundation and its Prostate Cancer Equity program, visit www.admetech.org.

Join us for a special edition of “Prostate Cancer and You,” a podcast in honor of Prostate Cancer Awareness Month 2024. In this episode, we dive into one man’s personal journey, from active surveillance to cutting-edge PSMA PET technology, to shape his treatment plan. Since its establishment in 1999 and official recognition as National Prostate Cancer Awareness Month in 2003, this annual observance serves as a crucial reminder of the ongoing fight against prostate cancer and the importance of staying informed.

This podcast is brought to you in part by Blue Earth Diagnostics. For more information on POSLUMA, including the Important Safety Information and full Prescribing Information, visit www.posluma.com/patient.

Today’s podcast in the “Prostate Cancer and You” series, brought to you in part by Blue Earth Diagnostics, features Dr. David Yang, attending physician in the Department of Radiation Oncology at Brigham and Women’s Hospital/Dana-Farber Cancer Institute, and Dr. Todd Cohen, Blue Earth Diagnostics vice-president of medical affairs. This conversation further explores the topics presented in the MPCC symposium session “AI Approaches for Research and Treatment.”